Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
32.11
67.33
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals Inc
Total Assets
Rhythm Pharmaceuticals Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
|
Total Assets
$363.6m
|
CAGR 3-Years
1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Assets
$143.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
19%
|
CAGR 10-Years
18%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Assets
$54.5B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Assets
$90.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
9%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Assets
$22.2B
|
CAGR 3-Years
21%
|
CAGR 5-Years
24%
|
CAGR 10-Years
25%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Assets
$37.4B
|
CAGR 3-Years
17%
|
CAGR 5-Years
22%
|
CAGR 10-Years
26%
|
|
Rhythm Pharmaceuticals Inc
Glance View
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. The company is headquartered in Boston, Massachusetts and currently employs 140 full-time employees. The company went IPO on 2017-10-05. The firm is focused on developing treatment for genetic diseases of obesity, which are characterized by early-onset, severe obesity and an insatiable hunger (hyperphagia). The Company’s lead product candidate, IMCIVREE (setmelanotide), is a potent melanocortin-4 receptor (MC4R). IMCIVREE is developed for the treatment of rare genetic diseases of obesity. The company is focused on the melanocortin-4 receptor (MC4R) pathway, which is responsible for regulating weight and hunger. The company targets the MC4R pathway to develop therapeutics for rare genetic diseases of obesity, including proopiomelanocortin (POMC) deficiency obesity, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl syndrome (BBS), Alstrom syndrome, POMC or LEPR heterozygous deficiency obesity, Smith-Magenis syndrome, steroid receptor coactivator 1 (SRC1) deficiency obesity, MC4R deficiency obesity and SH2B adapter protein 1 (SH2B1) deficiency obesity.
See Also
What is Rhythm Pharmaceuticals Inc's Total Assets?
Total Assets
363.6m
USD
Based on the financial report for Sep 30, 2024, Rhythm Pharmaceuticals Inc's Total Assets amounts to 363.6m USD.
What is Rhythm Pharmaceuticals Inc's Total Assets growth rate?
Total Assets CAGR 5Y
15%
Over the last year, the Total Assets growth was 3%. The average annual Total Assets growth rates for Rhythm Pharmaceuticals Inc have been 1% over the past three years , 15% over the past five years .
You don't have any saved screeners yet
